Last reviewed · How we verify

Raptiva — Competitive Intelligence Brief

Raptiva (Raptiva) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Immunology.

discontinued Leukocyte adhesion glycoprotein LFA-1 alpha Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Raptiva (Raptiva) — National Institute of Dental and Craniofacial Research (NIDCR).

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Raptiva TARGET Raptiva National Institute of Dental and Craniofacial Research (NIDCR) discontinued Leukocyte adhesion glycoprotein LFA-1 alpha
Hu1124 EFALIZUMAB Roche marketed CD11a-directed Humanized IgG1 Antibody Leukocyte adhesion glycoprotein LFA-1 alpha 2003-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Raptiva — Competitive Intelligence Brief. https://druglandscape.com/ci/raptiva. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: